

## EDITORS-IN-CHIEF

**Michael F. Drummond, MCom, DPhil**  
University of York

**C. Daniel Mullins, PhD**  
University of Maryland

## EDITORIAL STAFF

**Lyn Beamesderfer**  
Director, Publications

**Margaret M. Rafferty**  
Manager, Publications

**Jennifer A. Brandt**  
Associate, Publications

## ISPOR CORPORATE OFFICERS

**Nancy S. Berg**  
Chief Executive Officer/Executive Director

**Richard J. Willke, PhD**  
Chief Science Officer

**Laura T. Pizzi, PharmD, MPH**  
Associate Chief Science Officer

**Betsy Lane**  
Director and Chief Marketing &  
Communications Officer

**Sue Capon**  
Chief Operations Officer



**ISPOR**

Improving healthcare decisions

# CONTENTS

## REVIEWER ACKNOWLEDGMENT

### 321 Reviewer Acknowledgment

## THEMED SECTION: ARTIFICIAL INTELLIGENCE

### 328 The Value of Artificial Intelligence for Healthcare Decision Making—Lessons Learned

Danielle Whicher and Thomas Rapp

*The themed section on artificial intelligence (AI) includes 6 papers on the value of AI for healthcare and key barriers to its adoption.*

### 331 Assessing the Economic Value of Clinical Artificial Intelligence: Challenges and Opportunities

Nathaniel Hendrix, David L. Veenstra, Mindy Cheng, Nicholas C. Anderson, and Stéphane Verguet

*Economic evaluation of artificial intelligence will require methodological innovation, but health economists have an ideal skillset for shaping its cost-effective and equitable implementation.*

### 340 Systematic Review of Health Economic Evaluations Focused on Artificial Intelligence in Healthcare: The Tortoise and the Cheetah

Madelon M. Voets, Jeroen Veltman, Cornelis H. Slump, Sabine Siesling, and Hendrik Koffijberg

*Current health economic evaluations of artificial intelligence applications are limited in number and quality. Future evaluations need improvement to allow adoption into clinical practice.*

### 350 A Framework for Using Real-World Data and Health Outcomes Modeling to Evaluate Machine Learning–Based Risk Prediction Models

Patricia J. Rodriguez, David L. Veenstra, Patrick J. Heagerty, Christopher H. Goss, Kathleen J. Ramos, and Aasthaa Bansal

*The use of a high-performance machine learning–based risk prediction model for clinical decision making in cystic fibrosis is not expected to improve downstream patient outcomes.*

### 359 The Potential Cost-Effectiveness of a Machine Learning Tool That Can Prevent Untimely Intensive Care Unit Discharge

Juliette de Vos, Laurenske A. Visser, Aletta A. de Beer, Mattia Fornasa, Patrick J. Thoral, Paul W.G. Elbers, and Giovanni Cinà

*The authors present an early cost-effectiveness analysis of a machine learning model that may guide intensivists in their decision-making process on the most appropriate time to discharge a patient in an intensive care unit.*

# Value in Health CONTENTS (continued)

**368 Fulfilling the Promise of Artificial Intelligence in the Health Sector: Let's Get Real**

Tiago Cravo Oliveira Hashiguchi, Jillian Oderkirk, and Luke Slawomirski

*Artificial intelligence in the health sector is still nascent. To ensure it adds value, policy makers need to proactively manage a range of risks and barriers.*

**374 Do People Favor Artificial Intelligence Over Physicians? A Survey Among the General Population and Their View on Artificial Intelligence in Medicine**

Derya Yakar, Yfke P. Ongena, Thomas C. Kwee, and Marieke Haan

*This paper discusses what the general public's attitude is toward the use of artificial intelligence in medicine.*

## EDITORIAL

**382 Estimating the Economic Value of CDX2 as a Predictive Biomarker to Guide Treatment Decisions in Stage II Colon Cancer**

Piero Dalerba

*CDX2 represents a cost-effective biomarker for the selection of patients with stage II colon cancer to be treated with adjuvant chemotherapy under a wide range of realistic scenarios.*

## BRIEF REPORT

**385 The Use of Cost-Effectiveness Thresholds for Evaluating Health Interventions in Low- and Middle-Income Countries From 2015 to 2020: A Review**

Joseph Kazibwe, Adrian Gheorghe, David Wilson, Francis Ruiz, Kalipso Chalkidou, and Y-Ling Chi

*A review of the use of cost-effectiveness thresholds for evaluating health interventions in low- and middle-income countries from 2015 to 2020.*

## COMPARATIVE-EFFECTIVENESS RESEARCH/HTA

**390 Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England**

Renske M.T. ten Ham, Geert W.J. Frederix, Olivia Wu, Wim Goettsch, Hubert G.M. Leufkens, Olaf H. Klungel, and Jarno Hoekman

*This research aimed to identify key considerations underlying the reimbursement recommendations in the health technology assessment of advanced therapies.*

**400 Does Every Minute Really Count? Road Time as an Indicator for the Economic Value of Emergency Medical Services**

David Swan and Luc Baumstark

*This study measures the impact of response time on patient outcomes for a wide range of emergency medical service interventions.*

### Mission Statement

*As the official journal of ISPOR, Value in Health provides a forum for researchers, healthcare decision makers, and policy makers to apply health economics and outcomes research to healthcare decisions.*

# Value in Health CONTENTS (continued)

## ECONOMIC EVALUATION

- 409 CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness Analysis**  
Fernando Alarid-Escudero, Deborah Schrag, and Karen M. Kuntz  
*Testing patients with stage II colon cancer for the absence of CDX2 expression followed by adjuvant chemotherapy to the subgroup found CDX2-negative is a cost-effective and high-value management strategy.*
- 419 Economic Evaluation of National Patient Blood Management Clinical Guidelines in Cardiac Surgery**  
Adam H. Irving, Anthony Harris, Dennis Petrie, Alisa Higgins, Julian A. Smith, Lavinia Tran, Christopher M. Reid, and Zoe K. McQuilten  
*The authors present an economic evaluation of National Patient Blood Management Clinical Guidelines using a large, national cardiac surgery registry in Australia.*
- 427 Incentivizing Prescription Drug Switching to Reduce Patient and Health Plan Spending: A Microsimulation Model**  
Kai Yeung and Ernesto Ulloa  
*Direct patient payments can incentivize patients to switch from higher cost drugs to lower cost therapeutic alternatives, generating both patient and health plan savings.*

## METHODOLOGY

- 435 Performance of the UK Prospective Diabetes Study Outcomes Model 2 in a Contemporary UK Type 2 Diabetes Trial Cohort**  
Mi Jun Keng, Jose Leal, Marion Mafham, Louise Bowman, Jane Armitage, and Borislava Mihaylova  
*External validation of the UK Prospective Diabetes Study Outcomes Model 2 in people with type 2 diabetes in the ASCEND trial found mortality and cardiovascular outcomes to be overpredicted.*

## PREFERENCE-BASED ASSESSMENTS

- 443 Assessing Payers' Preferences for Real-World Evidence in the United States: A Discrete Choice Experiment**  
Enrique M. Saldarriaga, Brett Hauber, Josh J. Carlson, Douglas Barthold, David L. Veenstra, and Beth Devine  
*The authors explore the payers' preferences for real-world evidence studies and quantify the value payers' place on key real-world evidence attributes.*
- 451 Investigating 5-Level EQ-5D (EQ-5D-5L) Values Based on Preferences of Patients With Heart Disease**  
Mihir Gandhi, Ru San Tan, Shir Lynn Lim, Kim Rand, Carolyn S.P. Lam, Nan Luo, and Yin Bun Cheung  
*The authors provide a 5-level EQ-5D value set using preferences of patients with heart disease.*



# Value in Health CONTENTS (continued)

## SYSTEMATIC LITERATURE REVIEW

**461 Genetic-Guided Pharmacotherapy for Atrial Fibrillation: A Systematic and Critical Review of Economic Evaluations**

Ahmad Amir Kamil, Ka Keat Lim, Rositsa Koleva-Kolarova, Philip Chowienczyk, Charles D.A. Wolfe, and Julia Fox-Rushby

*The authors examine the extent and quality of evidence from economic evaluations of genetic-guided pharmacotherapy for atrial fibrillation and identified variables influential in changing base-case conclusions.*



**ISPOR**

*Improving healthcare decisions*